A phase III randomized study of EC [epirubicin + cyclophosphamide] followed by paclitaxel versus FEC [fluorouracil + epirubicin + cyclophosphamide] followed by paclitaxel, all given either every 3 weeks or 2 weeks supported by pegfilgrastim, for node positive breast cancer patients

Trial Profile

A phase III randomized study of EC [epirubicin + cyclophosphamide] followed by paclitaxel versus FEC [fluorouracil + epirubicin + cyclophosphamide] followed by paclitaxel, all given either every 3 weeks or 2 weeks supported by pegfilgrastim, for node positive breast cancer patients

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Pegfilgrastim (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms GIM2
  • Most Recent Events

    • 09 Dec 2016 Results of pooled analysis from this and other study (MIG1 and GIM2) published in the European Journal of Cancer.
    • 25 Aug 2014 Status changed from active, no longer recruiting to completed as reported at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2014 Results of a single center substudy on timing of administration presented at presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top